Cogent Biosciences (COGT) Stock Price, News & Analysis

Company Overview

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors. Preclinical studies have demonstrated the candidate’s ability to deplete immunosuppressive macrophages within the tumor microenvironment, resulting in antitumor activity as a monotherapy and in combination with checkpoint inhibitors. Cogent continues to explore additional novel small molecules that can influence immune-regulatory pathways in oncology.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences completed its initial public offering in 2020 and maintains operations in key U.S. research hubs. The company leverages collaborative partnerships with academic institutions and contract research organizations to advance its pipeline efficiently. While most of its clinical programs are currently being evaluated in North America, Cogent is positioned to pursue international trial sites as it progresses through later-stage development.

Under the leadership of President and Chief Executive Officer Daniel Welch, Cogent Biosciences is guided by a management team with deep experience in oncology drug development, translational research, and regulatory strategy. The company’s board and scientific advisory committees include experts in immuno-oncology and precision medicine, supporting its mission to bring novel targeted therapies to patients with unmet medical needs.

Key Stats

• Today's Range: $39.87 to $40.89
• 50-Day Range: $31.02 to $40.51
• 52-Week Range: $10.38 to $43.73
• Volume: 3.87 million shs
• Average Volume: 3.08 million shs
• Market Capitalization: $6.92 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.73
• Consensus Rating: Moderate Buy

Cogent Biosciences Stock Analysis - MarketRank™

Cogent Biosciences scored higher than 17% of companies evaluated by MarketBeat, and ranked 762nd out of 845 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 9 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Cogent Biosciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Cogent Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cogent Biosciences are expected to grow in the coming year, from ($2.26) to ($1.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cogent Biosciences is -18.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cogent Biosciences is -18.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cogent Biosciences has a P/B Ratio of 10.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.43% of the float of Cogent Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cogent Biosciences has a short interest ratio ("days to cover") of 5.81.

Change versus previous month

Short interest in Cogent Biosciences has recently increased by 16.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cogent Biosciences does not currently pay a dividend.

Dividend Growth

Cogent Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for COGT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cogent Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.59% of the stock of Cogent Biosciences is held by insiders.

Percentage Held by Institutions

Cogent Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 7/09/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COGT
• CIK: 1622229
• Web: www.cogint.com
• Phone: (617) 945-5576
• Fax: N/A
• Employees: 80
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Cogent Biosciences: $43.73
• High Price Target: $67.00
• Low Price Target: $20.00
• Potential Upside/Downside: +7.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$328.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -104.27%
• Return on Assets: -54.64%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 15.14
• Quick Ratio: 15.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.84 per share
• Price / Book: 10.55

Miscellaneous

• Outstanding Shares: 170,870,000
• Free Float: 159,608,000
• Market Cap: $6.92 billion
• Optionable: Optionable
• Beta: 0.34